Two meningococcal B vaccines are available in the US: Bexsero, manufactured by GlaxoSmithKline, contains OMV components; the other vaccine, Trumenba made by Wyeth Pharmaceuticals, does not.

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

This vaccine targets serogroup B, a fifth strain of the meningococcal bacteria. It's recommended for certain high-risk groups, such as college freshmen living in dorms. The CDC suggests teens get ...

The new meningococcal vaccines protect against infections caused by this bacteria. ... B, C, W and Y. The vaccine was approved by the Food and Drug Administration last week for ages 10 through 25.

A partial vaccination series (single serogroup B meningococcal outer membrane vesicle vaccine [MenB-4C] dose) was 26% effective against gonorrhea, while a complete vaccination series (two MenB-4C ...

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...

While vaccines for the A, W, Y and C strains are covered under the National Immunisation Program, the vaccine for the meningococcal B strain can currently cost between $100 to $200 per person.

PORTLAND, Ore. — A vaccine that prevents meningococcal B infection may also protect against gonorrhea, according to a new study by the Oregon Health Authority. The research followed ...